Cite
HARVARD Citation
Panaccione, R. et al. (n.d.). P433 Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's disease. Journal of Crohn's and colitis. p. i560. [Online].